Cabozantinib, which simultaneously targets MET and VEGFR2, has demonstrated limited inhibitory effects on tumors in clinical trials for GBM patients who are not receiving anti-angiogenic therapy (NCT00704288).155. Here, MET is linked to glioblastoma.